Skip to main content
Independent federal grant matching. Not affiliated with any government agency. Get free access and see which open grants fit your organization.
Open for applications

First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)

National Institutes of Health · Opportunity number PAR-25-180

View the official notice on Grants.gov
364 days left (deadline Oct 15, 2027)

Details summarized from the official notice as of Oct 15, 2026. Always confirm eligibility, deadlines and requirements in the official notice before applying.

Independent platform. Not affiliated with or endorsed by any government agency. Data from public federal sources.

Key facts

Opportunity numberPAR-25-180
AgencyNational Institutes of Health
Department of Health and Human Services
Assistance listing (ALN, formerly CFDA)93.242
PostedNov 26, 2024
DeadlineOct 15, 2027
Cost sharing or matching requiredNo
Funding typeCooperative agreement
CategoryHealth
Last updated hereOct 15, 2026

Summary from the notice

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs, or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The NOFO will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase II studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drugs impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The NOFO also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding for further clinical development as FDA-approved treatments. A key aspect of this NOFO is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.

Who can apply

The official notice lists these applicant types as eligible:

  • County governments
  • Public and Indian housing authorities
  • Private colleges and universities
  • Federally recognized tribal governments
  • Others named in the notice (see the eligibility text)
  • Nonprofits without 501(c)(3) status (other than colleges)
  • Public and state colleges and universities
  • State governments
  • Small businesses
  • City or township governments
  • For-profit organizations other than small businesses
  • Nonprofits with 501(c)(3) status (other than colleges)
  • Special district governments
  • Independent school districts
  • Other Native American tribal organizations

Who should take a closer look

  • Small businesses
  • Nonprofits
  • Colleges and universities
  • State governments
  • Local governments
  • Tribal governments and organizations
  • Larger for-profit companies

Not listed as eligible

  • Individuals

Unless the eligibility text in the notice names you, this opportunity is probably not for you.

Eligibility details from the notice

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Registrations you will likely need

Most applications submitted through Grants.gov need the following. Registration can take several weeks, so start early. The notice lists the exact requirements.

Similar open opportunities

Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)

National Institutes of Health · PAR-25-155

Deadline: Oct 19, 2026 (3 days left) Up to: $50,000 Health

Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

National Institutes of Health · RFA-CA-27-021

Deadline: Oct 19, 2026 (3 days left) Up to: $600,000 Health

Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

National Institutes of Health · RFA-CA-27-020

Deadline: Oct 19, 2026 (3 days left) Up to: $600,000 Health